{"content":[{"text":"Visterra Announces Publication in the Journal PLOS Neglected Tropical \n Diseases Demonstrating that Novel Antibody, VIS513, Broadly Neutralizes \n Antibody-Enhanced Dengue Infection in Preclinical Studies","bbox":{"left":0.136221,"top":0.162217,"width":0.7275079999999999,"height":0.06007000000000001}},{"text":"Cambridge, MA – February 12, 2018 – Visterra, Inc., a clinical-stage biotechnology company, \n announced that new preclinical results with VIS513, its novel monoclonal antibody in development \n for the treatment of dengue, were published online in the journal PLOS Neglected Tropical Diseases \n (Y. Budigi et al., PLoS Negl Trop Dis 12(2): e0006209. https://doi.org/10.1371/journal.pntd.0006209). In \n the paper titled “Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype \n reactive monoclonal antibody targeting domain III of the dengue E protein,” Visterra scientists and \n scientists at the National University of Singapore (NUS), the Singapore-MIT Alliance for Research \n and Technology (SMART) Center, and Duke-National University of Singapore (Duke-NUS) \n describe preclinical data demonstrating that VIS513 potently neutralized dengue virus at clinically \n relevant viral loads. More importantly, dengue virus neutralization by VIS513 was demonstrated in \n the presence of natural antibody that can potentially enhance dengue infection and lead to more \n severe disease. These data support the continued development of VIS513 as a single administration \n treatment for dengue virus infection.","bbox":{"left":0.105882,"top":0.243165,"width":0.787932,"height":0.22587}},{"text":"“Dengue is the most common mosquito-transmitted viral disease in the world, currently with no \n specific treatment, and prevention is solely dependent on effective mosquito control measures,” said \n Zach Shriver, PhD, Chief Scientific Officer at Visterra. “These new preclinical data further \n demonstrate the ability of VIS513 to effectively neutralize dengue virus, independent of serotype, \n with potentially lower likelihood of the virus developing resistance to VIS513. In addition, these \n results differentiate VIS513 from what others have shown – in vitro and in animal models – that at \n certain concentrations, other antibodies bind, but do not neutralize, the dengue virus and \n consequently enhance, or worsen, dengue virus infection. We are especially encouraged by these \n preclinical data demonstrating that VIS513 broadly neutralizes antibody-enhanced dengue \n infection.”","bbox":{"left":0.105882,"top":0.487104,"width":0.7862370000000001,"height":0.173446}},{"text":"About VIS513 \n Developed using Visterra’s Hierotope platform, VIS513 is an engineered humanized antibody that \n targets a conserved region on dengue virus domain III of the E protein that is present across all \n dengue virus serotypes. In preclinical studies, VIS513 has demonstrated that it potently neutralized \n all four serotypes of dengue virus and protected animals challenged with a lethal dose of dengue \n virus. VIS513 is being developed under a collaboration with the Serum Institute of India, who \n expects to initiate clinical trials of VIS513 in 2018.","bbox":{"left":0.105882,"top":0.67862,"width":0.781393,"height":0.12132399999999999}},{"text":"About Dengue \n Dengue is a mosquito-borne viral infection found in tropical and sub-tropical regions around the \n world. There are four distinct, but related, serotypes of the virus, each of which can cause dengue. \n The virus infects cells of the human immune system and other cell types, leading to symptoms that \n include high fever, severe headache, severe pain behind the eyes, joint pain, muscle and bone pain,","bbox":{"left":0.105882,"top":0.818013,"width":0.7752749999999999,"height":0.086476}}],"images_bbox":[{"left":0.091373,"top":0.081818,"width":0.261176,"height":0.064545}],"images_bbox_not_text_overlap":[{"left":0.091373,"top":0.081818,"width":0.261176,"height":0.064545}]}